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ABSTRACT: Amorphous materials exhibit distinct physico-
chemical properties compared to their respective crystalline
counterparts. One of these properties, the increased solubility
of amorphous materials, is exploited in the pharmaceutical
industry as a way of increasing bioavailability of poorly water-
soluble drugs. Despite the increasing interest in drug
amorphization, the analytical physicochemical toolbox is
lacking a reliable method for direct amorphous solubility
assessment. Here, we show, for the ﬁrst time, a direct approach
to measure the amorphous solubility of diverse drugs by
combining optics with ﬂuidics, the single particle analysis
(SPA) method. Moreover, a comparison was made to a
theoretical estimation based on thermal analysis and to a
standardized supersaturation and precipitation method. We
have found a good level of agreement between the three methods. Importantly, the SPA method allowed for the ﬁrst
experimental measurement of the amorphous solubility for griseofulvin, a fast crystallizing drug, without the use of a
crystallization inhibitor. In conclusion, the SPA approach enables rapid and straightforward determination of the
supersaturation potential for amorphous materials of less than 0.1 mg, which could prove highly beneﬁcial in the ﬁelds of
materials science, analytical chemistry, physical chemistry, food science, pharmaceutical science, and others.
In materials science, amorphous solids lack the three-dimensional long-range order characteristic for crystalline
solids. The two materials, having the same molecular
composition, possess distinctly diﬀerent physicochemical
properties. The properties of amorphous materials are
successfully exploited in many ﬁelds, ranging from the
electronics, nuclear, chemical, and pharmaceutical indus-
tries.1−6 The pharmaceutical industry is exploiting one speciﬁc
property of amorphous materials, their increased solubility
compared to the respective crystalline materials (often referred
to as “apparent solubility”), to enhance the bioavailability of
poorly water-soluble drugs.7,8 However, the available phys-
icochemical analytical toolbox lacks a method that would
enable direct measurement of amorphous solubility, the
maximum drug concentration in solution upon dissolution of
amorphous solid. Here, we use a novel technique, combining
the ﬁelds of optics and ﬂuidics, to measure amorphous
solubility.
Upon dissolution of an amorphous material, a super-
saturated solution with a higher chemical potential (μsup)
compared to a solution at thermodynamic equilibrium (μeq) is
generated (eq 1).9−12 The diﬀerence in chemical potential
(Δμ) is deﬁned as shown in eq 2, where R is the gas constant,
T is the temperature, and asup and aeq are the activity of the
solute in a supersaturated state and at the thermodynamic
equilibrium, respectively.13 For suﬃciently dilute solutions, the
activities of the solute in the supersaturated and equilibrium
states can be replaced by the respective concentrations of the
solute. Therefore, eq 2 can be written as eq 3, where Csup is the
drug concentration in solution at the point of supersaturation,
and Ceq is the drug concentration in solution at the
thermodynamic equilibrium; the ratio between these two
concentrations is the degree of supersaturation (DS).
Δμ = μ − μsup eq (1)
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Before the maximum DS in solution is reached, crystal-
lization of solute molecules can occur. This phenomenon has
resulted in diﬃculties in experimentally determining the
maximum DS of amorphous solids when using classical
dissolution experiments, as observed by Murdande et al.10,14
The maximum DS can alternatively be estimated from data
acquired by thermal analysis of the crystalline and respective
amorphous samples. An initial method was developed by
Hoﬀman et al.,15 and this was later improved by Murdande et
al.10 by taking into account the eﬀects of moisture sorption and
ionization. As might be expected, the theoretically estimated
amorphous solubilities have been higher than the experimen-
tally achieved values.9,14,16 Therefore, the accurate experimen-
tal measurement of amorphous solubility, especially for fast
crystallizing drugs, has gained the general status of
“unattainable”.17
Nevertheless, Almeida et al. reported the ﬁrst experimental
measurement of amorphous solubility of griseofulvin (GRI), a
fast crystallizing drug.18 They assessed amorphous solubility by
investigating phase separation phenomena upon precipitation
using ﬂuorescent probes. However, a crystallization inhibitor to
prevent GRI from crystallizing during the experiment had to be
used. Another approach to study drug supersaturation, the
standardized supersaturation and precipitation method
(SSPM), in which drug predissolved in organic solvent is
added to aqueous buﬀer and the onset of precipitation is
detected, was developed by Palmelund et al.19 The method has
been developed for a standardized comparison of super-
saturation duration and DS between diﬀerent compounds
under certain conditions, e.g., in biorelevant media or in the
presence of precipitation inhibitors, rather than for the exact
measurement of the drug’s amorphous solubility.
Until now, the direct experimental measurement of
amorphous solubility has not been accomplished. The
hypothesis that this still is possible is based on the fusion of
ﬂuidics and optics, resulting in development of the novel
image-based single particle analysis (SPA) method.20 The
method is able to measure the equilibrium solubility of
crystalline compounds requiring only a very low amount of
material (<0.1 mg) with the measurement starting as soon as
the material comes in contact with the solvent.20,21 During the
measurement, particles of interest are entrapped in the ﬂow-
through compartment of a speciﬁcally designed cell that
enables simultaneous extraction of the solvent, maintaining
sink conditions, and imaging of the dissolving particles. The
obtained images are then further processed with an in-house
developed algorithm, and solubility values are generated.
Here, using the SPA method, we show the ﬁrst direct
measurements of amorphous solubility of a diverse range of
drugs. Moreover, we compare the results obtained with the
SPA method to the theoretically estimated values obtained via
thermal analysis, as well as the values estimated with the SSPM
method. In this way, we show the suitability of the SPA
method for direct measurement of amorphous solubility.
■ MATERIALS AND METHODS
Materials. Celecoxib (CEL) was acquired from AK
Scientiﬁc, Inc. (Union City, CA, USA). Danazol (DAN) was
acquired from BASF (Ludwigshafen, Germany). Dipyridamole
(DIP), GRI, and indomethacin (IND) were acquired from
Sigma-Aldrich (St. Louis, MO, USA). These compounds were
selected to represent the acidic, basic, and neutral nature of
drug compounds. Moreover, the selected compounds can be
made amorphous without signiﬁcant degradation by melting
and cooling. GRI was also selected due to its fast crystallization
kinetics from the amorphous form.14,18
Preparation of Amorphous Forms. The received
crystalline forms of the compounds were heated in an
aluminum sample holder on a hot plate to slightly above
their respective melting points until complete melting was
observed. The melt was then immersed in liquid nitrogen and
placed in a desiccator over phosphorus pentoxide. After the
nitrogen had evaporated, the sample was equilibrated to room
temperature and gently ground with a mortar and pestle before
being further analyzed.
Diﬀerential Scanning Calorimetry (DSC). DSC experi-
ments were performed using a DSC823e (Mettler-Toledo,
Greifensee, Switzerland) equipped with a refrigerated cooling
system (Julabo FT 900, Seelbach, Germany). Nitrogen was
used as a purge gas (50 mL/min).
Samples of 5−10 mg were tightly packed into standard
aluminum crucibles (40 μL) with pierced lids. The samples
were equilibrated at 25 °C for 3 min and then linearly heated
with a heating rate of 10 °C/min to 20 °C above their
respective melting points. Measurements of both amorphous
and crystalline samples were recorded in triplicate, and thermal
events were analyzed using the STARe software (Mettler-
Toledo, Greifensee, Switzerland). Temperatures and melting
enthalpies were used to estimate the free energy diﬀerence
between the amorphous and crystalline forms.
X-ray Powder Diﬀraction (XRPD). XRPD diﬀractograms
were recorded using an Aerius diﬀractometer (Malvern
Panalytical B.V., Almelo, The Netherlands) using Cu Kα
radiation (λ = 1.540598 Å) and a divergence slit of 0.5°.
Samples were packed into aluminum sample holders and
measured with a step size of 0.0066° at 40 kV and 7.5 mA from
5° to 35° (2θ). Measurements were performed in triplicates
with independent samples.
Dynamic Water Sorption (DVS). The water sorption
isotherms of the ﬁve amorphous drug samples were
determined using the method previously described by
Murdande et al.10 A VTI-SA+ Vapor Sorption Analyzer (TA
Instruments, New Castle, DE, USA) was used to measure the
moisture sorption proﬁles of the amorphous samples.
Approximately 10 mg of amorphous sample was placed into
a glass holder. To reduce the possibility of sample
crystallization during the measurement, no drying step was
used. The DVS measurements were performed at 25 °C from 0
to 95% relative humidity (in 10% steps up to 90%). The
equilibrium criterion was 0.001% weight change in 5 min with
a maximum step time of 150 min. The instrument is calibrated
once a month.
Dissolution Media. HCl and borate buﬀers (pH 2.0 and
pH 9.0, respectively) were prepared according to the United
States Pharmacopeia (Solutions/Buﬀer Solutions). Milli-Q
water was obtained with the Milli-Q Integral 15 system
(MilliporeSigma, Burlington, MA, USA).
Equilibrium Solubility. The equilibirum solubilities of the
ﬁve model compounds were measured employing a shake-ﬂask
method, using a μDISS Proﬁler (Pion Inc., Billerica, MA, USA)
at 22 °C. For CEL, DAN, GRI, and IND, an excess amount of
crystalline compound was added to 10 mL of USP pH 2.0
buﬀer. For DIP, an excess amount of crystalline compound was
added to 10 mL of USP pH 9.0 buﬀer. The excess amount for
all compounds was 2.2 ± 0.2 mg and the buﬀer’s pH was
selected such that the intrinsic solubility, i.e., the solubility of
Analytical Chemistry Article
DOI: 10.1021/acs.analchem.9b01378
Anal. Chem. 2019, 91, 7411−7417
7412
the un-ionized form, was measured. The concentrations of all
compounds were measured, at least in triplicate, until a plateau
in the dissolution curve was reached. Each probe of the μDISS
device was individually calibrated for each compound. The
area under the curve of the second derivative of absorbance
was used for calibration in order to avoid interference of the
excess drug. Experimental settings are listed in Table S1.
Supersaturation Study Using SSPM. Determination of
the initial dimethyl sulfoxide (DMSO) concentration (C100%)
for the supersaturation studies was done as described by
Palmelund et al.19 First, the C100% stock solution of each
compound was determined such that addition of 200 μL of the
compound in the DMSO solution to the buﬀer would result in
precipitation within 1−5 min. Consecutively, stock solutions
that resulted in C87.5%, C75.0%, and C50.0% upon addition
of 200 μL of predissolved drug in DMSO to 10 mL of the
buﬀer were prepared. Additionally, stock solutions correspond-
ing to C30.0% for CEL and, C60.0% for DIP and GRI were
prepared. The total volume of DMSO added was kept at 2%
for all experiments. Upon spiking the buﬀer with the stock
solution, the concentration was monitored in situ with the
μDISS Proﬁler (Pion Inc., Billerica, MA, USA) by using the
area under the curve of the second derivative of the UV
absorbance for 60 min or longer, if no precipitation had
occurred.
The determination of induction time of precipitation (tind) is
limited by the experimental conditions.19 Here, a slightly
diﬀerent approach to that originally proposed by Palmelund et
al. to determine tind was developed.
19 The time-point of the
sharpest decrease in concentration was determined as the local
minimum of the ﬁrst derivative of the concentration versus
time plot using Matlab software (MathWorks, Natick, MA,
US) (Figure S1). The crystallization rate was subsequently
calculated using the slope of the linear trend-line ﬁtted to 12
data points around the point of the steepest decrease in
concentration. Consequently, the tind was deﬁned as the point
where the ﬁtted trend-line crossed the initial concentration
value.
Image-Based SPA Solubility Measurements. Dissolu-
tion experiments were conducted using the SPA method as
described previously by Svanbac̈k et al. and Štukelj et al.21,22
Brieﬂy, the method consists of an image-analysis algorithm and
a ﬂow-through setup, which enables imaging of the ﬁxed drug
particles under constant ﬂow conditions (Figure S2). The
constant ﬂow continuously displaces drug molecules from the
surface of the dissolving particle. This enables, via the analysis
of the image series, for the concentration of the solute to be
measured at the particle-solution interface (for a more detailed
description, see Supporting Information S-2). According to the
Noyes and Whitney diﬀusion layer theory, the measured
concentration is the thermodynamic equilibrium solubility of a
crystalline compound.22−24 Consequently, with the amorphous
material, the concentration at the interface is equal to the
maximum achievable drug concentration in solution−amor-
phous solubility. (Figure 1).
The solubilities of all ﬁve crystalline and amorphous samples
were measured in triplicate in Milli-Q water. Moreover, the
solubilities of CEL, DAN, GRI, and IND were measured in
USP buﬀer pH 2.0, and the solubility of DIP was measured in
USP buﬀer pH 9.0. The obtained solubility values, therefore,
were the average of three independent measurements, where at
least ten particles per single measurement were analyzed.
Additionally, amorphous IND was also measured in HCl buﬀer
pH 2.0 in the presence of 0.1% (w/v) polyvinylpyrolidone
(PVP). The additional measurement using PVP was performed
in order to assess the need for a crystallization inhibitor in the
SPA experiments.
■ RESULTS AND DISCUSSION
Characterization of Solid-State Forms. The results of
the solid-state characterization of the ﬁve model compounds,
in both crystalline and amorphous form, are presented in
Figure 2 and summarized in Table 1. The results are in good
agreement with previously reported XRPD and DSC data on
these compounds.14,16,25 Furthermore, the XRPD diﬀracto-
grams of the crystalline forms of DAN, DIP, GRI, and IND
match the predicted diﬀractograms for the corresponding
structures in the Cambridge Structural Database (CSD),
YAPZEU, BIRKES10, GRISFL, and INDMET01, respectively.
For crystalline CEL, the CSD-predicted XRPD powder pattern
(DIBBUL) exhibits substantially diﬀerent relative peak
intensities compared to our experimental data, presumably
due to preferred orientation eﬀects of the needle shaped
particles.26 Nonetheless, the diﬀraction pattern of CEL in this
study has three sharp diﬀraction peaks that indicate the
thermodynamically stable crystalline form of CEL.27,28
Amorphous samples were devoid of diﬀraction peaks, and all
showed a glass transition, followed by crystallization and
melting (Figure 2 and Table 1).
Validation of the SPA Method. The equilibrium
solubilities of the crystalline compounds were measured with
the shake-ﬂask method and compared to the equilibrium
solubilities measured with the SPA method (Figure 3a). There
was no signiﬁcant diﬀerence in the standard deviation for the
SPA (M = 0.51 μg/mL, SD = 0.35 μg/mL) and the shake-ﬂask
method (M = 0.27 μg/mL, SD = 0.12 μg/mL) conditions; t(4)
= 1.72, p = 0.16. A correlation coeﬃcient (R2) of 0.996 was
Figure 1. Crystalline and amorphous particle depicted at the
beginning and after 10 min of the SPA measurement. As the
dissolution occurs in the controlled environment with sink conditions,
the only rate limiting step is the concentration at the particle−solution
interface. With the thermodynamically most stable crystalline form,
the concentration at the interface is equal to the thermodynamic
equilibrium concentration. Consequently, with the amorphous
material, the concentration at the interface is equal to the maximum
achievable drug supersaturation in solution upon amorphization.
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observed, validating the SPA method for measuring the
thermodynamic equilibrium solubility of the selected crystal-
line model compounds. Moreover, the solubility of amorphous
IND was measured in both USP HCl buﬀer pH 2.0 and the
same buﬀer with PVP (0.1% (w/v)) added (Figure 3b). PVP
acts as a crystallization inhibitor during the dissolution of
amorphous material.29 The presence of PVP in the dissolution
medium did not aﬀect the solubility of amorphous IND
measured with the SPA method. The result suggests that the
SPA method is able to directly measure the amorphous
solubility of a drug, without the need for crystallization
inhibitors.
To rationalize the solubility values for amorphous forms
obtained with the SPA method, the amorphous solubilities of
the ﬁve model drugs were approached in three diﬀerent ways,
(1) theoretical estimation using the Hoﬀman method
corrected for the impact of absorbed water on amorphous
solute, (2) indirect measurement using the modiﬁed SSPM,
and (3) direct measurement with the SPA method. Moreover,
a comparison was made also to other attempts of measuring
amorphous solubility reported in literature.10,16,18,31 To
facilitate comparison of amorphous solubility between the
selected model compounds, the DS with respect to
thermodynamic equilibrium solubility was used.
Theoretical Estimation of DS. According to Hoﬀman, the
diﬀerence in Gibbs free energy (ΔG) between the crystalline
and the amorphous form can be estimated using eq 4.15 Hm,
Tm, and T are the melting enthalpy of the crystalline form, the
melting temperature of the crystalline form, and the
experimental temperature measured in Kelvin, respectively.
Using the ΔG estimation, the maximum DS due to
Figure 2. (a) XRPD diﬀractograms of amorphous (orange) and
crystalline (blue) drug samples. (b) DSC thermograms of amorphous
(orange) and crystalline (blue) drug samples. The zoomed-in
endothermic event for crystalline dipyridamole is due to evaporation
of water from the sample.
Table 1. Distinct XRPD Peak Positions, Glass Transition (Tg), and Crystallization Temperatures (Tc) of Amorphous Samples
and Temperature of Melting (Tm) and Enthalpy of Melting (ΔHm) for Crystalline Samplesa
XRPD DSC
compound distinct peak positions (°2θ) Tg (°C) Tc (°C) Tm (°C) ΔHm (J/g)
celecoxib 5.4, 16.2, 21.6 48.9 ± 1.7 101.2 ± 0.1 161.4 ± 0.2 99.1 ± 1.0
danazol 13.5, 15.8, 18.9 74.2 ± 1.1 105.6 ± 0.2 226.8 ± 0.3 102.5 ± 2.4
dipyridamole 8.1, 8.9, 17.5 41.7 ± 1.3 80.5 ± 2.4 165.6 ± 0.1 60.1 ± 0.9
griseofulvin 10.8, 14.6, 16,5 89.0 ± 1.2 123.3 ± 0.4 217.6 ± 0.3 114.4 ± 2.0
indomethacin 11.6, 17.0, 19.6 36.4 ± 0.6 116.2 ± 0.3 159.8 ± 0.2 102.3 ± 4.5
aThe Tg value is given as the midpoint temperature of the step change in heat capacity of the DSC thermograms. For Tc and Tm, onset
temperatures are listed.
Figure 3. (a) Correlation between the equilibrium solubility
measured with the SPA method and the shake-ﬂask method using
the μDISS Proﬁler. (b) Apparent equilibrium solubility of amorphous
IND measured in USP buﬀer pH 2.0 and USP buﬀer pH 2.0 with
added PVP 0.1% (m/v) using the SPA method. Error bars represent
one standard deviation.
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amorphization was predicted according to Hancock and Parks9
and corrected for the impact of water on the amorphous solute
as proposed by Murdande et al. through eq 5.10 R and
exp(−I(a2)) are the gas constant and a correction factor
obtained from DVS measurements, as shown by Murdande et
al.10 The calculated values are listed in Table 2.
Δ = × − ×G H T T T
T
( )m m
m
2
(4)
= ×−Δ −e eDS G RT I a/ ( )2 (5)
Indirect Measurement of DS Using the Modiﬁed
SSPM. The modiﬁed SSPM measurement is considered
indirect, since the maximum DS was not directly measured
but rather extrapolated. The tind of each model compound at a
certain DS was estimated from the dissolution proﬁle, as
described in the Materials and Methods section. DS values for
the respective stock solutions of each compound were
calculated and plotted against tind (Figure S3). The ﬁtted
curves follow eq 6, derived from classical nucleation theory
assuming tind is inversely proportional to the nucleation rate,
with α and β being the two linear coeﬃcients.19,31,32 In order
to estimate the maximum DS, a linear trend line was ﬁtted only
to the points that would fall within the horizontal region of the
ﬁt according to eq 6 (Figure S4). Otherwise, an estimation of
the maximum DS would not be possible, since the nucleation
theory results in inﬁnite DS with inﬁnitesimal tind. The
estimated maximum DS values are listed in Table 2.
= α β+
−
t eind
ln(DS) 2
(6)
Direct Measurement of DS Using the SPA Method.
The solubilities of the amorphous and crystalline samples were
measured in Milli-Q water and USP buﬀers as soon as the
solvent came in contact with particles. The DS upon
amorphization was calculated using eq 3. The calculated DS
values for each of the model compounds are summarized in
Table 2.
Eﬀect of Ionization. The solubility ratio between two
polymorphs of the same compound is independent of the
solvent used.33 On the other hand, Murdande et al. proposed
an eﬀect of ionization on the DS with respect to amorphous vs
crystalline materials.10 In this study, the USP buﬀers were used
in a way that any possible ionization eﬀect was avoided, and
drugs were in their respective un-ionized forms. Furthermore,
close agreement between the DS values observed in Milli-Q
water and USP buﬀers with the SPA method was observed
(Table 2). No ionization eﬀect on DS was detected with the
SPA method; the diﬀerence between the DS in Milli-Q and DS
in USP buﬀers is the same for ionizable drugs (CEL, DIP, and
IND) as for the neutral drugs (DAN and GRI).
Onset of Crystallization. The literature values for DS
upon amorphization obtained with classical dissolution of
amorphous material and measurement of concentration
overtime are lower than the DS values measured by the SPA
method, the modiﬁed SSPM, as well as the theoretical
estimation (Table 2). The reason for this is that, in classical
dissolution measurements, crystallization may start before the
maximum DS in solution is reached.9,10,16 With the modiﬁed
SSPM, the issue of instantaneous precipitation, when the
solution is close to the maximum DS, was avoided by
measuring the precipitation onset of solutions with DS below
the maximum DS. In contrast to classical dissolution
experiments, measurements with the SPA method were
conducted as soon as the solvent came in contact with the
sample in order to circumvent any possible solid-state
transformations during the measurements.
Successful Measurement of DS with the SPA Method.
For three compounds, CEL, DAN, and IND, the DS values
obtained with the SPA method (22.3, 21.9, and 22.6,
respectively), the adapted SSPM method (20.6, 21.5, and
22.3, respectively), and the theoretical estimation (21.7, 23.9,
and 18.7, respectively) show high correlation (Table 2). For
CEL, the DS range, 7−21, reported in the literature was
obtained over a temperature range of 34−75 °C.18 The
relevant temperature range for comparison with this study is
below the Tg of the drug, with the predicted DS value of 21
listed in Table 2. In contrast, for DIP, the DS values obtained
with the SPA (17.2) and adapted SSPM (17.3) methods are in
close agreement, but the theoretically estimated value is
signiﬁcantly lower (6.6).
A possible reason for the inconsistency in DS values for DIP
could be the fact that the Hoﬀman method assumes that the
heat capacities (Cp) of the crystalline and amorphous material
are the same. The assumption might lead to inaccurate ΔG
estimation, especially for compounds with a signiﬁcant
diﬀerence in Cp between the crystalline and amorphous
forms. An approach that is free of such Cp assumptions was
developed by Almeida et al.18 Nevertheless, despite the
assumption of uniform Cp for crystalline and amorphous
forms, the Hoﬀman method has been found to provide a good
estimate of the ΔG.34 Moreover, for another drug used in this
study (GRI), the Hoﬀman method and the approach by
Almeida et al. gave similar values of DS upon amorphization
(34.6 and 30.9, respectively).
Another reason for the discrepancy between the theoretically
estimated and the experimentally measured DS of DIP could
be the hygroscopicity of the sample. DIP is highly hygroscopic,
Table 2. DS Measured with the SPA Method, the Modiﬁed SSPM, and Theoretically Estimated According to the Hoﬀman
Method with Correction for the Eﬀect of Water on the Amorphous Solute, and DS Values Found in the Literaturea
SPA method SSPM theoretical estimation literature
compound milli-Qb USP buﬀer USP buﬀer N/A dissolution in water theoretical estimation
CEL 18.9 22.3e 20.6e 21.7 3.1c,h 21g,h
DAN 18.3 21.9e 21.5e 23.9 3.0d,i 26.5i
DIP 15.3 17.2f 17.3f 6.6 10k
GRI 29.8 34.3e 5.9e 34.6 1.4d,i 29.1i, 30.9j
IND 20.4 23.6e 22.3e 18.7 4.9d,i 20.8i
aCEL, celecoxib; DAN, danazol; DIP, dipyridamole; GRI, griseofulvin; and IND, indomethacin. bMilli-Q-ultrapure water, type 1. cDistilled water.
dDeionized water. eUSP HCl buﬀer pH 2.0. fUSP borate buﬀer pH 9.0. gPredicted value below the Tg of the drug.
hRef 16. iRef 10. jRef 18. kRef
30.
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which can be observed as evaporation of adsorbed water from
the surface of crystalline material leading to the highlighted
endothermic event slightly above 100 °C in the DSC plot
(Figure 2). Furthermore, the DVS experiment also showed the
high aﬃnity of amorphous DIP for water, which resulted in
sample mass loss (0.39%) above RH 80%; upon crystallization,
water was expelled from the sample resulting in weight loss
(Figure S5). The results suggest that the correction for the
impact of water on the highly hygroscopic amorphous sample
might overcorrect the DS. To follow up on this assumption,
the estimated DS based solely on the ΔG, without the
correction for the adsorbed water, was calculated. A value of
15.2 was obtained, which is much closer to the experimentally
measured DS with the SPA method and the one estimated
with the adapted SSPM method.
Amorphous Solubility of the Rapidly Crystallizing
GRI. Using the SPA method, without any crystallization
inhibitor present in the medium, a DS of 34.3 for GRI was
obtained. The DS value was in good agreement with the value
estimated according to the Hoﬀman method (34.6). In
contrast, the DS estimated with the modiﬁed SSPM was
much lower at 5.9. GRI is known for its fast crystallization
kinetics, which is most likely the reason for the low maximum
DS observed by the adapted SSPM method. This might be
prevented with the addition of a crystallization inhibitor, as was
done with hydroxypropyl methylcellulose acetate succinate
grade HF (HPMCAS-HF) by Almeida et al.18 They attempted
to indirectly measure amorphous solubility by looking at the
phase separation phenomena upon precipitation using
ﬂuorescent probes as they added drugs dissolved in organic
solvent to the aqueous buﬀers. When using crystallization
inhibitors, it is important to evaluate if the obtained higher DS
is actually due to inhibition of crystallization and not due to a
solubility enhancing eﬀect of these compounds. Nonetheless,
the DS for GRI, obtained by Almeida et al. (30.8) is close to
that measured with the SPA method (34.3).
■ CONCLUSION
In this study, we have demonstrated the suitability of the SPA
method for direct measurement of solubility of amorphous
materials. The amorphous solubilities of ﬁve model drug
compounds were assessed using three diﬀerent approaches, the
theoretical estimation using the Hoﬀman method, indirect
measurement using the modiﬁed SSPM method, and direct
measurement using the SPA method. For CEL, DAN, and
IND, the amorphous solubility values correlated for all three
methods used. For DIP, the theoretically estimated DS was,
most likely due to the hygroscopic nature of the sample, and
signiﬁcantly lower when compared to the values obtained with
the adapted SSPM and the SPA method, which were in
agreement with one another. On the other hand, for GRI, the
SPA method was in agreement with the Hoﬀman method but
not the adapted SSPM method due to fast crystallization
kinetics of the drug.
The SPA method used in this study represents a new
approach for direct experimental measurement of amorphous
solubility. The SPA method is especially useful when the
material of interest crystallizes quickly upon dissolution, which
can mask its true supersaturation potential with established
solubility measurement methods. GRI, a fast crystallizing drug,
was successfully analyzed in this work, and for the ﬁrst time, its
amorphous solubility was experimentally determined without
the use of crystallization inhibitors.
The straightforward approach to measure amorphous
solubility using the SPA method provides insights in the
supersaturation potential that a certain drug candidate (or
indeed any other material) possesses. This, now easily
extracted, piece of information is of high value in the drug
formulation process and could result in more optimized drug
products. Moreover, the method has much potential in the
ﬁelds of materials science, analytical chemistry, physical
chemistry, food science, and other ﬁelds where amorphization,
solubility, and supersaturation play a signiﬁcant role.
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